PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Liver function”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,315 records · Page 73Linked to original sources
PubMed1998

[Liver function and the level of total cholesterol in the blood serum in liver cirrhosis].

The authors have analyzed findings from a laboratory examination of 50 subjects presenting with different affections of the liver. Correlation is established between the level of total cholesterol and activity of alanine aminotransferase in blood serum of cirrhotic patients, it being particularly clear in portal cirrhosis (r = -0.85; P < 0.05), as well as significantly higher levels of total and indirect bilirubin and lower level of albumins in patients presenting with a reduced level of total cholesterol. This allows the decrease in the blood serum content of total cholesterol to be regarded as an unfavourable index in hepatocirrhosis.

Adult↗
PubMedDate not supplied

[Change in the gastrointestinal tract and liver functions of animals due to dithiocarbamic acid derivatives].

The TMTD does not change the secretory activity of the dogs' stomach with its one-time administration by mouth in doses of 0.5--10 mg/kg. With its multiple introduction (10 mg per kg once a day for a space of consecutive 30 days) the secretion of juice increases, while the pepsin content in the juice of dags diminishes. The DEDCS, EEDMDCA, TMTD and EBDCC (singly into the stomach in a dose of 1l5LD50 per kg) bring down the glycogen-forming and secretory function of the liver in rats and inhibit the propulsive activity of the intestines in mice, stimulated with 5-oxytryptophan. The mechanism of the intestinal motor activity inhibition is caused by the inhibition of oxytryptophandecarboxylase (CP 4.1.1.28) in the intestines of the animals with the DTCA derivatives.

Animals↗
PubMed1982

[Effect of gamma therapy on liver function in the combined treatment of cancer of the cardia and esophagus].

The effects of preoperative gamma-therapy and gastrostomy performed in Dobromyslov-Torek's operation on the function of the liver were studied by histological and histochemical examination of material obtained in biopsy of liver and biochemical assays of blood in a study group including 40 patients with cardial cancer and 9 cases of esophageal tumor. It was shown that both preoperative irradiation and gastrostomy-mediated nutrition cause pronounced morphological lesions of liver tissue. Although biochemical indices remain within norm, the compensatory capability of liver in such patients is lower than in unexposed ones.

Adult↗
PubMedDate not supplied

Evaluation of liver function for the application of preoperative portal vein embolization on major hepatic resection.

BACKGROUND/AIMS: Although preoperative portal vein embolization has been employed for hepatectomy to increase the safety of the surgery, patient selection criteria for hepatectomy following portal vein embolization have still not been established. In this study liver functional tests before and after portal vein embolization were evaluated in order to determine their influence on the outcome of subsequent hepatectomy and the prognostic potential of this approach. METHODOLOGY: Forty-five patients, who had undergone major hepatic resection after embolizing the right portal branch, were divided into the following 3 groups according to their postoperative course: complication(-), complication(+), and liver failure group. Clinical, analytical, and hemodynamic parameters obtained before and after portal vein embolization were compared between the three groups. RESULTS: Significant differences were found between the complication(-) group and the liver failure group for 8 factors, and statistically significant cut-off points distinguishing the liver failure group could be determined. Based upon values measured before PVE these were: 1) portal pressure > 16 cmH2O; 2) pre-PVE serum cholinesterase < 160 U/L; 3) pre-PVE serum hyaluronate > 130 ng/mL. Based on values measured after PVE they were: 1) a hypertrophic ratio of the left lobe < 1.21; 2) post-PVE ICGR15 (%) > 16%; 3) a portal pressure measured immediately after PVE > 25 cmH2O; 4) post-PVE serum cholinesterase < 160 U/L; 5) post-PVE serum hyaluronate > 160 ng/mL. Discriminant function analysis in a stepwise manner showed that the portal pressure and serum levels of hyaluronate measured before and after portal vein embolization were the most useful in prediction of the outcome of the following hepatectomy. CONCLUSIONS: Patients whose data match the above criteria before portal vein embolization should be excluded as candidates for major hepatic resection with portal vein embolization. Even after portal vein embolization in patients whose data match post-portal vein embolization criteria major hepatic resection may have to be abandoned, or the extent of the hepatic resection reconsidered.

Adult↗
PubMed1994

Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation.

We used the polymerase chain reaction (PCR) to determine the presence of hepatitis C virus (HCV)-RNA in serum samples obtained from 19 patients with leukaemia or severe aplastic anaemia and investigated the correlation between HCV status and the results of liver function tests after bone marrow transplantation. PCR analysis of serum samples obtained before transplant showed that 10 of 18 patients were HCV-RNA-positive; 5 of these patients had developed acute post-transfusion hepatitis 1-11 months before transplant. An additional patient was HCV-RNA-positive on post-transplant day 62. Eight HCV-RNA-positive patients had pre-transplant GPT levels above the upper limit of normal. In these patients the GPT decreased significantly from a median of 104 IU/l (54-822 IU/l) pre-transplant to 23 IU/l (15-56 IU/l) on post-transplant days 8-12. In 9 of 11 HCV-RNA-positive patients, the GPT increased transiently from days 40 to 50 and again increased after day 100. Two of these patients died from hepatic failure; the GPT levels normalised in 3 patients after day 300 but continued to fluctuate in 4 patients. In the remaining 2 HCV-RNA-positive patients, the GPT remained close to the normal range throughout the follow-up period. Three HCV-RNA-positive patients became HCV-RNA-negative after 1-3 years. In these patients, the GPT remained normal for > 3 years after day 300.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMedDate not supplied

Hepatic inflow vessels caliber as an index for liver function.

BACKGROUND/AIMS: Little is known about the serial change of the hepatic inflow vessels' caliber in the chronically diseased liver. We have analyzed the caliber change in patients with esophageal varices and examined relationship between hepatic inflow vessels diameter and age of patients who had no liver disease. MATERIALS AND METHODS: (i) Diameters of the hepatic inflow vessels was measured on angiogram in five patients with chronic liver disease. They underwent liver angiography twice with an interval of more than 10 months. The caliber change was analyzed. (ii) Thirty-nine patients without chronic liver disease were analyzed to examine vessel diameter change with aging. RESULTS: (i) The left hepatic artery diameter increased in size during the follow-up periods. On the other hand, the portal vein caliber increased in three cases excluding two cases whose Child grade did not change from A. (ii) The hepatic artery and the portal vein diameter had a tendency to become smaller with aging in thirty-nine patients who underwent hepatic angiography and had no liver disease. CONCLUSIONS: Hepatic inflow vessels' caliber change, particularly increase in hepatic artery diameter, has a potential of suggesting the liver function to some extent.

Chronic Disease↗
PubMed2005

Coagulation profile and liver function in 102 patients after total cavopulmonary connection at mid term follow up.

OBJECTIVE: To examine coagulation factors and liver function test abnormalities in patients after total cavopulmonary connection (TCPC). DESIGN: Cross sectional study comprising clinical and echocardiographic evaluation, and biochemical and coagulation profile screening. SETTING: Tertiary referral centre. METHODS: 102 patients aged 4-24 years (median 10 years) at one to eight years (median five years) after TCPC were examined. All patients were maintained on a low dose of aspirin. 96% of patients were in a good clinical condition (New York Heart Association class I or II). No intracardiac thrombi were detected on echocardiography and ventricular function was good in 91% of patients. RESULTS: Total bilirubin was increased in 27% and gamma glutamyltransferase in 54% of patients. Serum total protein, albumin, and prealbumin were normal in almost in all patients. Compared with the control group, patients after TCPC had significantly lower fibrinogen, factor V, factor VII, and protein C concentrations, prolonged international normalised ratio, and increased antithrombin III concentration. Factor V concentration was abnormally decreased in 35%, factor VII in 16%, and protein C in 28% of patients. Antithrombin III was increased in 23% of patients. Factor VII, factor V, protein C, and antithrombin III correlated significantly with serum prealbumin. There was also a significant correlation between procoagulant factor VII and both anticoagulant protein C and antithrombin III. CONCLUSIONS: Almost half of patients after TCPC had laboratory signs of mild cholestasis. Decreased liver synthesis of procoagulant and anticoagulant factors was observed but overall coagulation homeostasis appeared to be in balance in this selected group of patients with a good clinical outcome.

Adolescent↗
PubMed1995

Seroprevalence of hepatitis A, B, C, and D markers and liver function abnormalities in intravenous heroin addicts.

To determine the most prevalent forms of hepatitis in intravenous heroin addicts, 389 addicts consecutively admitted to outpatient treatment clinics throughout California were tested for antibodies to hepatitis A (anti-HAV), B core (anti-HBc), B surface (anti-HBs), C (anti-HCV), D (anti-HDV), and B surface antigen (HBsAg). The majority were also tested for serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, lactic dehydrogenase, total bilirubin, globulins, albumin, and platelet count. The seroprevalence of each marker was: anti-HAV (40.7%); anti-Hbc (73.6%); anti-HBs (46.7%); anti-HCV (93.6%); anti-HDV (9.6%), and HBsAg (3.5%). No single case was positive for IgM, anti-HAV, or for both HBsAg and anti-HDV, indicating the presence of recent hepatitis A or hepatitis D infection. Abnormal liver enzymes, serum proteins, total bilirubin, and platelet count were found to be normal in 5.3 to 44.8% of anti-HCV cases indicating persistent infection. Among anti-HCV cases, elevated total bilirubin or a low platelet count was invariably associated with one or more liver enzyme and protein abnormalities. We conclude that while acute hepatitis may be frequent and caused by various viral types, hepatitis C is the primary form of chronic hepatitis found in intravenous heroin addicts. Almost half of hepatitis C cases demonstrate liver function abnormalities indicating persistent infection that has the potential to be contagious and progress to cirrhosis, liver failure, and hepatocellular carcinoma.

Adult↗